UNSPSC 51281904: Olivomycin

This classification denotes a dna minor groove binding agent and antineoplastic antibiotic with the molecular formula C58H84O26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44003517D1, chemically known as olivomycin d, 3(b)-o-(2,6-dideoxy-3-c-methyl-4-o-(2-methyl-1-oxopropyl)-alpha-l-arabino-hexopyranosyl)- but generally known as olivomycin, which bears US NIH Compound Identifier 122806. European Medicines Agency schedules Olivomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03507MIG.

UNSPSC 51281904 Olivomycin is a Commodity code representing a specific pharmaceutical product. State and local government procurement activity under this code centers on acquiring olivomycin as a therapeutic pharmaceutical for use in health programs administered by state health and human services agencies. The Texas Health and Human Services Commission has recently issued a Request for Information (RFI) exploring vendor capabilities for direct-to-manufacturer prescription programs, indicating state interest in establishing alternative supply channels for pharmaceutical products outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements. The RFI solicits vendor experience with direct contracting for self-insured employers and health plans, negotiated net pricing models without rebates, and value-based or outcomes-based agreements. This exploration suggests state procurement interest extends to reshaping how pharmaceutical commodities, including specialty drugs, reach end users within state employee health plans and Medicaid programs.

Activity under this code appears limited in the recent state and local procurement record. The single identified recent opportunity is the Texas Health and Human Services Commission's March 2026 RFI (HHS0017013), which closed April 3, 2026, and functions as a market-intelligence gathering phase rather than a formal competitive solicitation. The RFI does not specify award values, budget ranges, or binding procurement timelines, as it is designed to inform the state's future strategy before issuing a formal RFP. Geographic visibility is concentrated in Texas, and issuing-body activity is limited to state health departments at present. Olivomycin as a named pharmaceutical commodity sees minimal discrete procurement volume in state and local records, suggesting either narrow clinical application, specialized dispensing channels, or incorporation into broader pharmaceutical supply agreements not tagged to individual drug codes.